FY 2022 results reflect consistent progress towards its main objectives, with first commercial sales of synthetic DNA and its Hermes™ nanoparticles, and it is on track to be able to produce GMP-grade DNA by end 2023. It generated revenues of £0.3m with a pre-tax loss of £5.9m (vs. £3.5m) and ended the period with £4.4m cash. A €23m loan facility provides it with a cash runway into 2025. We have made changes to forecasts to reflect increased investment in R&D and commercial headcount and reiterat ....
